請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72951
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 朱清良 | |
dc.contributor.author | Jo-Ning Wu | en |
dc.contributor.author | 吳若寧 | zh_TW |
dc.date.accessioned | 2021-06-17T07:11:30Z | - |
dc.date.available | 2024-08-26 | |
dc.date.copyright | 2019-08-26 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-19 | |
dc.identifier.citation | 1.Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387-402.
2.Berton G, Mócsai A, Lowell CA. Src and Syk kinases: key regulators of phagocytic cell activation. Trends in Immunology. 2005;26(4):208-14. 3.Martin Turner ES, Francesco Colucci, James P. Di Santo, Tybulewicz aVL. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunology Today. 2003;vol.21 N0.3:148. 4.Yi YS, Son YJ, Ryou C, Sung GH, Kim JH, Cho JY. Functional roles of Syk in macrophage-mediated inflammatory responses. Mediators Inflamm. 2014;2014:270302. 5.Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proceedings of the National Academy of Sciences. 2010;107(7):2902-7. 6.Ennaciri J, Girard D. IL-4R , a New Member that Associates with Syk Kinase: Implication in IL-4-Induced Human Neutrophil Functions. The Journal of Immunology. 2009;183(8):5261-9. 7.Yin H, Zhou H, Kang Y, Zhang X, Duan X, Alnabhan R, et al. Syk negatively regulates TLR4-mediated IFNbeta and IL-10 production and promotes inflammatory responses in dendritic cells. Biochim Biophys Acta. 2016;1860(3):588-98. 8.Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94-108. 9.Paiva C, Rowland T, Danilova O, Sreekantham B, Spurgeon SE, Danilov AV. SYK Inhibition Disrupts the Cross-Talk Between B-Cell Activation Factor (BAFF) and B-Cell Receptor (BCR) and Thereby Antagonizes Mcl-1 in Chronic Lymphocytic Leukemia (CLL) B-Cells. Blood. 2016;128(22):303. 10.Murray PJ. Macrophage Polarization. Annu Rev Physiol. 2017;79:541-66. 11.Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20. 12.Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-69. 13.Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. Int J Biol Sci. 2014;10(5):520-9. 14.Tarique AA, Logan J, Thomas E, Holt PG, Sly PD, Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am J Respir Cell Mol Biol. 2015;53(5):676-88. 15.Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-37. 16.Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593-604. 17.Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 2010;11(10):936-44. 18.Huang Stanley C-C, Smith Amber M, Everts B, Colonna M, Pearce Erika L, Schilling Joel D, et al. Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation. Immunity. 2016;45(4):817-30. 19.Van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, et al. Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages. Cell Rep. 2016;17(3):684-96. 20.Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Reports. 2014;6. 21.Lowell CA. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol. 2011;3(3). 22.Asai A, Nakamura K, Kobayashi M, Herndon DN, Suzuki F. CCL1 released from M2b macrophages is essentially required for the maintenance of their properties. J Leukoc Biol. 2012;92(4):859-67. 23.Wu WK, Llewellyn OP, Bates DO, Nicholson LB, Dick AD. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology. 2010;215(9-10):796-803. 24.Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient Clearance of Early Apoptotic Cells by Human Macrophages Requires M2c Polarization and MerTK Induction. The Journal of Immunology. 2012;189(7):3508-20. 25.Dorothe´e Duluc YD, Fang Tan, Marie-Pierre Moles, Linda Grimaud, Julien Lenoir, Laurence Preisser, Ignacio Anegon, Laurent Catala,Norbert Ifrah, Philippe Descamps, Erick Gamelin,, Hugues Gascan MHaPJ. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like. Blood. 2007; VOLUME 110, NUMBER 13. 26.Huang X, Li Y, Fu M, Xin H-B. Polarizing Macrophages In Vitro. In: Rousselet G, editor. Macrophages: Methods and Protocols. New York, NY: Springer New York; 2018. p. 119-26. 27.Ferrante CJ, Pinhal-Enfield G, Elson G, Cronstein BN, Hasko G, Outram S, et al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling. Inflammation. 2013;36(4):921-31. 28.Ann Kelly-Welch EMH, and Achsah D. Keegan*. Interleukin-4 (IL-4) Pathway. Science's STKE. 2005;Vol. 2005, Issue 293. 29.Knipper JA, Willenborg S, Brinckmann J, Bloch W, Maass T, Wagener R, et al. Interleukin-4 Receptor alpha Signaling in Myeloid Cells Controls Collagen Fibril Assembly in Skin Repair. Immunity. 2015;43(4):803-16. 30.McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75(1):38-50. 31.Yan D, Wang H-W, Bowman Robert L, Joyce Johanna A. STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation. Cell Reports. 2016;16(11):2914-27. 32.Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, et al. Antagonizing Integrin beta3 Increases Immunosuppression in Cancer. Cancer Res. 2016;76(12):3484-95. 33.Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease. Annual Review of Immunology. 2011;29(1):71-109. 34.Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and Related Cytokines and Receptors. Annual Review of Immunology. 2004;22(1):929-79. 35.Xu W, Roos A, Schlagwein N, Woltman AM, Daha MR, van Kooten C. IL-10–producing macrophages preferentially clear early apoptotic cells. Blood. 2006;107(12):4930-7. 36.Fuss IJ, Boirivant M, Lacy B, Strober W. The Interrelated Roles of TGF-β and IL-10 in the Regulation of Experimental Colitis. The Journal of Immunology. 2002;168(2):900-8. 37.Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356(6337):513-9. 38.Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood. 2010;116(17):3311-20. 39.Dickensheets H, Vazquez N, Sheikh F, Gingras S, Murray PJ, Ryan JJ, et al. Suppressor of cytokine signaling-1 is an IL-4-inducible gene in macrophages and feedback inhibits IL-4 signaling. Genes And Immunity. 2006;8:21. 40.Hesketh M, Sahin KB, West ZE, Murray RZ. Macrophage Phenotypes Regulate Scar Formation and Chronic Wound Healing. International Journal of Molecular Sciences. 2017;18(7). 41.Choi SH, Gonen A, Diehl CJ, Kim J, Almazan F, Witztum JL, et al. SYK regulates macrophage MHC-II expression via activation of autophagy in response to oxidized LDL. Autophagy. 2015;11(5):785-95. 42.Abram CL, Roberge GL, Hu Y, Lowell CA. Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. J Immunol Methods. 2014;408:89-100. 43.Faccio R, Zou W, Colaianni G, Teitelbaum SL, Patrick Ross F. High dose M-CSF partially rescues the Dap12?/? osteoclast phenotype. Journal of Cellular Biochemistry. 2003;90(5):871-83. 44.Balce DR, Li B, Allan ER, Rybicka JM, Krohn RM, Yates RM. Alternative activation of macrophages by IL-4 enhances the proteolytic capacity of their phagosomes through synergistic mechanisms. Blood. 2011;118(15):4199-208. 45.Ratthé C, Pelletier M, Chiasson S, Girard D. Molecular mechanisms involved in interleukin-4-induced human neutrophils: expression and regulation of suppressor of cytokine signaling. Journal of Leukocyte Biology. 2007;81(5):1287-96. 46.Dickensheets H, Vazquez N, Sheikh F, Gingras S, Murray PJ, Ryan JJ, et al. Suppressor of cytokine signaling-1 is an IL-4-inducible gene in macrophages and feedback inhibits IL-4 signaling. Genes And Immunity. 2006;8:21. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72951 | - |
dc.description.abstract | 脾酪氨酸激酶(Spleen Tyronsine kinase,Syk)為非受體酪氨酸激酶家族的一員,早期研究指出Syk 具有調控造血幹細胞增生、發育、分化等功能。後續研究則發現Syk不僅在造血幹細胞中為重要調控因子,同時也在免疫細胞中擔任重要的訊息傳遞蛋白。先前的研究發現Sykfl/fl LysM-Cre小鼠中骨髓細胞分化噬骨細胞數量銳減,同時巨噬細胞之免疫反應能力缺失,揭示Syk在巨噬細胞的發育和活化中為重要的調控因子。迄今,許多文獻發現巨噬細胞具有高度異質性,可分別藉由Th1以及Th2分泌的細胞激素極化為M1 和 M2 兩大族群 ,而其中於M1族群中Syk已在多篇文獻中被探討,並得知其參與在TLR4以及IFNα/β下游訊息傳遞; 然而,M2 族群Syk所扮演的角色尚未確立,因此我們欲藉由Sykfl/fl 以及 Syk∆LysM ,再進一步極化為M2中不同族群,對於發育、分化以及極化能力進行觀察,了解Syk 在M2族群中如何調控相關免疫反應。利用即時聚合酶連鎖反應(qPCR)以及流式細胞術(FCS)進行分析,不同刺激物下巨噬細胞極化為M1、M2a以及M2c之能力差異;針對功能性檢測則利用酵素免疫分析法(ELISA)和T淋巴球共培養實驗,觀察Syk 在細胞激素以及抑制T細胞增生之能力。本篇研究結果顯示Syk 缺失加劇巨噬細胞極化為M2,在M2a相關基因表達顯著上升,M1相關細胞表面標的蛋白-CD86則顯著下降,同時MHCII在M2a族群中高度表達。功能性檢測-T細胞共培養實驗下,M2a抑制T 細胞增生機制主要需藉由直接接觸,Syk 缺失之巨噬細胞抑制T細胞增生之能力有下降之趨勢,目前可能機制是Syk影響PD-L2表現量下降所導致。後續研究中,我們更進一步探討其中機制,發現 Syk 在IL-4刺激下活化,並且主導下游MAPK 以及Akt之活化狀態 | zh_TW |
dc.description.abstract | Spleen Tyrosine kinase (Syk), a non-receptor tyrosine kinase, has been recognized as a pivotal factor in various signal transductions and involved in the development, proliferation, and differentiation of hematopoietic stem cells. Many studies have shown that Syk played an important role in macrophage activation and function. Concomitantly, macrophages have been identified as heterogenous population with high plasticity and ability to polarized into diverse subsets in response to different stimulators respectively. Intense studies of Syk were focusing on M1 macropahges; whereas the role of Syk in M2 macrophages was still elusive. To dissect the role of Syk in M2 macropahges both polarization and activation, we have isolated bone marrow cells from Sykfl/fl and Syk∆LysM mice and developed into macrophages in vitro, and further polarized macrophages into different subsets. Real time polychain reaction(qPCR) and flow cytometry (FCS) have been applied to analyze differences between Sykfl/fl and Syk∆LysM macrophages polarization ability. Subsequently, ELISA and T cells co-culturing were conducted as functional assay to evaluate M2 macrophages activation state. According to our results, Syk deficient macrophages are less capable to polarize into M1 status and skews to M2a spectrum. Besides, we find CD86 expression is significantly lower in M1 subsets with MHCII significantly increase in M2a subsets at 24 hr. In functional analysis, we found that Syk deficient M2a compromise to suppress T cells proliferation. So far, we’ve hypothesized through lower PD-L2 expression in Syk deficient macrophages, and concomitantly we have also verified that direct interaction is necessary for M2a suppression ability. We took deeper look into IL-4 stimulated BMDMs unveiling the role of Syk in mediation of MAPK and Akt activation state. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:11:30Z (GMT). No. of bitstreams: 1 ntu-108-R06449012-1.pdf: 25800993 bytes, checksum: 1d5853e6c386ef0cfa48b8ca9c3897c5 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 誌謝 I
中文摘要 II Abstract III 目錄 IV 圖目錄 VIII ㄧ、背景資料(Introduction) 1 1. 脾酪氨酸激酶(SPLEEN TYROSINE KINASE, SYK) 1 2. 巨噬細胞(MACROPHAGE, MΦ) 2 2.1 M1細胞 3 2.2 M2細胞 3 2.2.1 M2a型態之巨噬細胞 4 2.2.2 M2b型態的巨噬細胞 4 2.2.3 M2c 型態之巨噬細胞 4 2.2.4 M2d型態之巨噬細胞 5 3. 介白素-4 (INTERLEUKIN 4, IL-4) 和介白素-4受體 5 4. 介白素-10 (INTERLEUKIN-10, IL-10) 和介白素-10 之受體 7 二. 研究動機(RATIONALE) 9 三、材料及方法 (Materials And Methods) 10 1.細胞培養及相關實驗 10 1.1 細胞株及試劑: 10 1.2 培養方式: 10 2.降低脾酪氨酸激酶(SYK)於THP-1表現量 11 3.細胞蛋白萃取及西方墨點法(WESTERN BLOT) 12 4.RNA 純化 及核酸序列定量偵測系統 13 5.實驗動物 16 6.分離小鼠骨髓幹細胞分化為巨噬細胞(MΦ) 16 7.巨噬細胞與T 細胞共培養實驗 18 7.1 T 細胞收集 18 7.2 巨噬細胞t 細胞共培養實驗 18 A. 直接接觸調控 18 B. 間接物質調控 19 8.細胞表面分子染色及流式細胞儀分析(FLOW CYTOMETRY ) 20 9.細胞激素測定及酵素免疫分析法(ELISA-LINKED IMMUNOSORBENT ASSAY, ELISA) 20 四.目標(Aims) 22 1.建立SYK∆LYSM小鼠與SYK FL/FL 小鼠骨髓細胞分化巨噬細胞方法 22 2.建立巨噬細胞M1、M2A以及M2C極化模式 22 3.分析M1、M2以及M2C 22 4.利用西方墨點法了解SYK可能參與途徑 23 五.實驗結果(Results) 24 1. 脾酪氨酸激酶條件敲除小鼠免疫細胞組成以及巨噬細胞體外培養系統 24 2. 脾酪氨酸激酶缺失之巨噬細胞極化為M1之能力不完全,並增強M2 MARKER表現量 24 3. 脾酪氨酸激酶缺失之替代性活化巨噬細胞抑制T細胞增生能力弱化 26 4. 脾酪氨酸激酶缺失之巨噬細胞受LPS刺激後M1子集分泌較多促發炎性細胞激素,以及各子集皆具有較高含量IL-10 28 5. 脾酪氨酸激酶參與IL-4下游MAPK訊息傳遞中 29 六.討論(Discussion) 31 七.圖表(Figures) 34 圖ㄧ. 脾酪氨酸激酶條件敲除小鼠免疫細胞組成以及巨噬細胞體外培養。 34 圖二. 早期脾酪氨酸激酶缺失之巨噬細胞極化為M1之能力不完全,並增強部分M2 相關表現量。 36 圖三.晚期脾酪氨酸激脢缺失之巨噬細胞極化為M1能力部分弱化,並加強部分M2相關表現量。 38 圖四. 脾酪氨酸激酶缺失之巨噬細胞M1指向分子表現較弱而M2指向分子並無差異。 40 圖五. 脾酪氨酸激酶缺失之替代性活化巨噬細胞抑制T細胞之能力弱化具劑量趨勢。 42 圖六. 脾酪氨酸激酶缺失之替代性活化巨噬細胞直接接觸抑制T細胞之能力弱化。 44 圖七. 脾酪氨酸激酶缺失之巨噬細胞受LPS刺激後M1子集分泌較多促發炎性細胞激素,以及各子集皆具有較高含量IL-10。 46 圖八. 脾酪氨酸激酶參與IL-4下游MAPK訊息傳遞,並同時影響AKT磷酸化。 47 八.參考資料 (Reference) 48 | |
dc.language.iso | zh-TW | |
dc.title | 探討脾酪氨酸激酶在替代性活化巨噬細胞中的角色 | zh_TW |
dc.title | The role of spleen tyrosine kinase in alternatively activated macrophages | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 許秉寧 | |
dc.contributor.oralexamcommittee | 陳俊任 | |
dc.subject.keyword | Sykfl/fl LysM-Cre小鼠,典型活化巨噬細胞,替代性活化巨噬細胞,介白素-4,介白素-10, | zh_TW |
dc.subject.keyword | Sykfl/fl LysM-Cre,Classically activated macrophage,Alternatively activated macrophage,Interleukin-4,Interleukin-10, | en |
dc.relation.page | 51 | |
dc.identifier.doi | 10.6342/NTU201901669 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 25.2 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。